//Your Connection to the Life Sciences Industry
Connect to IBC:LinkedIn iconTwitter iconFacebook iconBlog iconRSS icon
EmailPrint

Registration

Online Registration is Open!
Register by Friday, August 15 to Save Up to $700!
»Pricing Chart

Download Brochure

Add to Outlook Calendar

Find Another IBC Event

Vaccine Development & Production Summit

CSS

Disease and Pandemic Vaccine Research, Discovery and Innovation

December 08-09, 2014 · Hilton Boston Back Bay · Boston, MA

Event Overview

Event Overview

IBC's Vaccine Development & Production Summit continues to bring you new data on ways to achieve your development and production goals. This year, hear the challenges and triumphs of product developers who continue to advance their innovations to combat emerging and infectious diseases.

From the development of new cell lines to novel formulation strategies to process design and manufacturing considerations, IBC's Vaccine Development & Production Summit gives you access to applicable knowledge that you can readily apply to your own vaccine development portfolio.

brochure cover

Brochure Now Available
» Download Today!

Sample of Confirmed 2014 Speakers:

Manufacturing A Recombinant Measles Virus For Treating Patients With Multiple Myeloma
Mark J. Federspiel, Ph.D., Director, Viral Vector Production Laboratory, Mayo Clinic Comprehensive Cancer Center

Vaccine Adjuvant Science
Leonard Friedland, MD, Vice President, Scientific Affairs and Public Health Vaccines, GlaxoSmithKline

Designing the Next Generation of Vaccine Adjuvants
Derek T. O'Hagan, Ph.D., Vice President, Global Head of Vaccine Chemistry and Formulation Research, Novartis Vaccines

Development of a Malaria Transmission Blocking Vaccine as a Chemically Conjugated Nanoparticle
David L. Narum, Ph.D., Head of Process Development, Laboratory of Malaria Immunology and Vaccinology, NIH

Challenges Experienced During the Approval Process of a Novel Recombinant Influenza Vaccine
Penny Post, Ph.D., Director of Regulatory, Protein Sciences Corp.

Analytical Characterization of CHIKV VLP as a Vaccine Candidate
Sha Ha, Ph.D., Director, Merck

Exclusive Interview

Exclusive Interview with Manon M.J. Cox, President and CEO, Protein Sciences Corporation
Protein Sciences Corporation developed the world's first recombinant, highly purified, egg-free influenza vaccine, Flublok®, which the FDA regards as a technological advance in the manufacturing of an influenza vaccine.

Listen to a 7 minute exclusive interview with Manon M.J. Cox.:

Or download audio